8 77 85 96 96 96 92 80 0 20 40 60 80 100 0 1 4 8 12 16 20 24 Pooled 5 mg and 10 mg Patients, % Weeks 54 69 92 92 100 100 100 100 0 20 40 60 80 100 0 1 4 8 12 16 20 24 Patients, % Weeks Proportion of patients in the 5 and 10 mg (pooled) dose level achieving absence of IRF ≥90% of patients in the top two dose levels achieved absence of both intraretinal and subretinal fluid. A recurrence in IRF was observed in some patients 8 to 12 weeks after the last study treatment 26 26 26 26 26 25 25 25 Pooled 5 mg and 10 mg 26 26 26 26 26 25 25 25 Sample size Sample size Proportion of patients in the 5 and 10 mg (pooled) dose level achieving absence of SRF 9 Final results of the APEX study in MESI. Includes patients in the per protocol set that completed the Week 4 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). One patient in the 10 mg dose level discontinued after Week 12 due to recurrent uveitis flare-up.